Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
April 26 2023 - 4:05PM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel cancer
therapeutics generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that data from the Phase 1b study of ATRC-101 will be presented
during an oral abstract session at the American Society of Clinical
Oncology 2023 Annual Meeting, being held June 2-6, 2023 in Chicago,
Illinois.
Details of the presentation are as follows:
Abstract Title: Interim update
of the ATRC-101 phase 1b trial in advanced solid
tumors.Abstract Number:
2505Session: Developmental Therapeutics -
ImmunotherapyDate / Time: June 4, 2023; 9:45am –
12:45pm CDTPresenting
Author: Dr. Bartosz Chmielowski, Health
Sciences Clinical Professor of Medicine, Division of
Hematology-Oncology, University of California Los Angeles
About Atreca,
Inc.Atreca is a biopharmaceutical company developing novel
antibody-based therapeutics generated by its differentiated
discovery platform. Atreca's platform allows access to an
unexplored landscape in oncology through the identification of
unique antibody-target pairs generated by the human immune system
during an active immune response against tumors. These antibodies
provide the basis for first-in-class therapeutic candidates, such
as our lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking StatementsThis release contains
statements regarding matters that are not historical facts that are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, statements regarding
our strategy and future plans, including statements regarding the
development of ATRC-101, and our preclinical and clinical plans and
the timing thereof. Our actual results may differ materially from
those indicated in these forward-looking statements due to risks
and uncertainties related to the initiation, timing, progress and
results of our research and development programs, preclinical
studies, clinical trials, regulatory submissions, and other matters
that are described in our most recent Annual Report on Form 10-K
and Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) and available on the SEC's website at
www.sec.gov, including the risk factors set forth therein.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
Contacts
Atreca, Inc.Herb CrossChief Financial Officerinfo@atreca.com
Investors:Alex Gray, 650-779-9251agray@atreca.com
Media:Julia Fuller, 858-692-2001Julia@fordhutmanmedia.com
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024